{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058283","form_type":"8-K","ticker":"SENS","cik":"0001616543","company_name":"Senseonics Holdings, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.497889+00:00","generated_at":"2026-06-25T21:43:17.103476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Senseonics Q1 revenue $2.5M; FDA approves Eversense E3 6-month CGM","bullets":["Q1 2022 total revenue $2.5M vs $2.8M YoY; U.S. revenue $0.8M up from $0.3M.","Net income $86.7M ($0.19 EPS) vs net loss $249.5M (-$0.68 EPS) due to derivatives fair value adjustments.","FDA approved Eversense E3 CGM with 6-month sensor wear; U.S. commercial launch underway with Ascensia.","FY 2022 global revenue guidance reiterated at $14M-$18M.","Cash & investments $166.9M, debt $104.7M as of March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058283","json":"https://secwatch.observer/filing/0001104659-22-058283.json","markdown":"https://secwatch.observer/filing/0001104659-22-058283.md","text":"https://secwatch.observer/filing/0001104659-22-058283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616543/000110465922058283/0001104659-22-058283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616543/000110465922058283/tm2215050d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:43:17.103476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}